Drug Trial Radar · NCT07712705
HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis.
Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
515
Actual
Start
Apr 20, 2023
Primary completion
Sep 29, 2023
Study completion Feb 20, 2025
Sponsor
- Lead sponsor
- Newsoara Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if drug HPP737 works to treat moderate-to-severe plaque psoriasis in adults. It will also learn about the safety of drug HPP737. The main questions it aims to answer are: Does drug HPP737 improve psoriasis severity compared to a placebo at Week 16, as measured by the proportion of patients achieving a significant reduction in the Psoriasis Area and Severity Index (PASI) score? What medical problems do participants have when taking drug HPP737? Researchers will compare drug HPP737 to a placebo (a look-alike substance that contains no drug) to see if drug HPP737 works to treat moderate-to-severe plaque psoriasis. This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial. Participants will: Take drug HPP737 or a placebo orally every day Visit the clinic regularly for checkups and tests throughout the study Have their psoriasis severity assessed using standardized scoring tools, including the Psoriasis Area and Severity Index (PASI), static Physician's Global Assessment (sPGA), and Body Surface Area (BSA) Eligible participants are adults aged 18 years and older with a confirmed diagnosis of chronic plaque psoriasis for at least 6 months and moderate-to-severe disease at screening.
Conditions
- Psoriasis
Interventions
HPP737Drug
HPP737 capsule for oral administration
Placebo matching HPP737Drug
Placebo capsules matching HPP737 for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the proportion of subjects who achieve PASI 75 (a ≥ 75% reduction (improvement) in the Psoriasis Area and Severity Index (PASI) score )from baseline to Week 16Time frame: From enrollment to end of treatment at 16 weeks
Locations
50 sites in 1 country. Site status is shown where the registry gives one.
Beijing Friendship Hospital, Capital Medical University
Beijing, China
Beijing Tongren Hospital, Capital Medical University
Beijing, China
Peking University People's Hospital
Beijing, China
The First Affiliated Hospital of Bengbu Medical College
Bengbu, China
Cangzhou People's Hospital
Cangzhou, China
The Second Hospital of Jilin University
Changchun, China
The Second Xiangya Hospital of Central South University
Changsha, China
The Third Xiangya Hospital of Central South University
Changsha, China
Xiangya Hospital, Central South University
Changsha, China
Affiliated Hospital of Chengde Medical College
Chengde, China
Chengdu Second People's Hospital
Chengdu, China
Dongguan First People's Hospital
Dongguan, China
Shengli Oilfield Central Hospital
Dongying, China
The First Affiliated Hospital of Gannan Medical University
Gannan, China
Dermatology Hospital, Southern Medical University
Guangzhou, China
Guangdong Provincial People's Hospital
Guangzhou, China
The Sixth Affiliated Hospital of Sun Yat-sen University
Guangzhou, China
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, China
Affiliated Hospital of Guilin Medical University
Guilin, China
Shandong Provincial Hospital of Dermatology
Guiyang, China
Hangzhou First People's Hospital
Hangzhou, China
Hangzhou Third People's Hospital
Hangzhou, China
Zhejiang Provincial People's Hospital
Hangzhou, China
The Second Affiliated Hospital of Harbin Medical University
Harbin, China
Jiaxing First Hospital
Jiaxing, China
Jinan Central Hospital
Jinan, China
Shandong Provincial Hospital of Dermatology
Jinan, China
Shandong Provincial Hospital
Jinan, China
The First Affiliated Hospital of Kunming Medical University
Kunming, China
The First People's Hospital of Lianyungang
Lianyungang, China
Jiangxi Provincial Dermatology Hospital
Nanchang, China
Nanyang Central Hospital
Nanyang, China
Nanyang First People's Hospital
Nanyang, China
Shanghai Skin Disease Hospital
Shanghai, China
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM
Shanghai, China
The First Hospital of Hebei Medical University
Shijiazhuang, China
Shiyan People's Hospital
Shiyan, China
Suining Central Hospital
Suining, China
Affiliated Hospital of Tianjin Academy of Traditional Chinese Medicine
Tianjin, China
Wuhan First Hospital
Wuhan, China
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.